At Appeals Hearing, Myriad Outlines Stance on BRCA IP Rights for Whole-Genome Sequencing
April 06, 2011
At Appeals Hearing, Myriad Outlines Stance on BRCA IP Rights for Whole-Genome Sequencing
For the first time, before three federal circuit judges, Myriad stated its position on whether whole-genome sequencing assays that include BRCA mutations would infringe its patents.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- At Federal Circuit Hearing, Plaintiffs in Myriad Case Fight to Keep Gene Patentability Issue on the Table
July 25, 2012 / Pharmacogenomics Reporter - UPDATE: Appeals Court Decides Isolated DNA Patentable, Myriad's Analytical Method Claims Not
August 3, 2011 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - Federal Circuit Judges Considered USPTO Policy, Industry Impact in Ruling on Myriad's Gene Patents
August 22, 2012 / Pharmacogenomics Reporter - Appeals Court Says Prometheus Meets Machine/Transformation Test; Impact on Gene Patents Uncertain
December 22, 2010 / Pharmacogenomics Reporter